Mersana Therapeutics employs its biodegradable polymer platform (Fleximer®) to create new and better medicines. We are advancing our own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. We also leverage the versatility of Fleximer through partnerships to overcome the safety, efficacy, and delivery challenges of nucleic acids, biologics, and small molecules in numerous therapeutic areas.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblins™, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. We have two complementary platforms that provide access to these molecules. Firstly, we use our proprietary DNA-Programmed Chemistry™ (DPC™) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, we have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Nanopartz is a division of Concurrent Analytical Inc. The purpose of Concurrent Analytical Inc. is to commercialize the Ramanprobes technology to revolutionize point of care diagnostics. Nanopartz commercializes gold nanoparticles, particularly gold nanorods, for the research market. Specifically, the mission of Nanopartz is to commercialize therapeutic, imaging, and materials applications of newly patent pending, patented, or proprietary technologies in gold nanoparticles and gold nanorods for the life science and non-life science research markets.